Clinical Takeaway
This issue examines mounting evidence around GLP-1 receptor agonist therapy, with a focus on musculoskeletal risks during treatment, outcomes following discontinuation, and the cardiovascular implications of weight loss achieved through these agents. Rounding out the clinical picture, new findings from Lilly’s oral obesity candidate and emerging genetic data linking GLP-1 response to weight loss efficacy signal a rapidly evolving therapeutic landscape.
GLP-1 Digest | April 17, 2026
Dealing with a condition like this?
Dr. Caplan has worked with 30,000+ patients on conditions like this. A consultation starts with your specific situation — not a generic protocol.
Book a consultation →This issue examines mounting evidence around GLP-1 receptor agonist therapy, with a focus on musculoskeletal risks during treatment, outcomes following discontinuation, and the cardiovascular implications of weight loss achieved through these agents. Rounding out the clinical picture, new findings from Lilly’s oral obesity candidate and emerging genetic data linking GLP-1 response to weight loss efficacy signal a rapidly evolving therapeutic landscape.
GLP-1 News
- GLP-1 Receptor Agonist Clinical Evidence: Muscle Loss Risk
GLP-1 receptor agonists may increase muscle loss risk during weight reduction, requiring clinical consideration when prescribing semaglutide and tirzepatide for obesity treatment. - GLP-1 Receptor Agonist Discontinuation: What the Evidence Shows
GLP-1 receptor agonist discontinuation evidence is moderately relevant for prescribers managing obesity treatment with semaglutide and tirzepatide.
GLP-1 Studies
- GLP-1 Weight Loss Cardiovascular Evidence: Lilly Obesity Pill
GLP-1 receptor agonists and tirzepatide demonstrate weight loss efficacy in adults with obesity, with emerging evidence supporting cardiovascular benefits in randomized controlled trials. - GLP-1 Weight Loss Efficacy: Genetic Links Found
Summary Genetic factors influence individual responses to GLP-1 medications for weight loss, potentially enabling personalized treatment selection based on patient genetics.
